Talaris Therapeutics adds two board members

Two biotech leaders will help Talaris execute its Phase 3 trial in creating durable immunity in living donor kidney transplant recipients and pursue additional applications for its unique cell therapy.

Source: bizjournals.com Health Care:Biotechnology headlines - January 21, 2021 Category: Biotechnology Authors: Jason Thomas Source Type: news